(Q44548336)

4 December 2017

Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies (English)

1 reference

4 December 2017

1 reference

Elizabeth M Round

1

1 reference

4 December 2017

Samuel S Engel

2

1 reference

4 December 2017

Gregory T Golm

3

1 reference

4 December 2017

Michael J Davies

4

1 reference

4 December 2017

Keith D Kaufman

5

1 reference

4 December 2017

Barry J Goldstein

6

1 reference

4 December 2017

1 March 2014

1 reference

4 December 2017

1 reference

4 December 2017

31

1 reference

4 December 2017

3

1 reference

4 December 2017

203-214

1 reference

https://scigraph.springernature.com/pub.10.1007/s40266-014-0155-7

4 December 2017

0 references

cites work

The growing burden of diabetes mellitus in the US elderly population.

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

21 January 2018

Diabetes in older adults

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Longitudinal incidence and prevalence of adverse outcomes of diabetes mellitus in elderly patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Care of elderly patients with diabetes mellitus: a focus on frailty

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Management of type 2 diabetes mellitus in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Factors associated with initiation of antihyperglycaemic medication in UK patients with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Time to treatment initiation with oral antihyperglycaemic therapy in US patients with newly diagnosed type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Thiazolidinediones and PPARγ agonists: time for a reassessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Comparative analysis of two rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Oral antidiabetic treatment in type-2 diabetes in the elderly: balancing the need for glucose control and the risk of hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Insulin use in elderly adults: risk of hypoglycemia and strategies for care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of initial combination treatment with sitagliptin and pioglitazone--a factorial study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-014-0155-7

Trends in aging--United States and worldwide.

21 January 2018

1 reference

12 December 2020

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

1 reference

12 December 2020

Guidelines for Improving the Care of the Older Person with Diabetes Mellitus

1 reference

12 December 2020

Heart Failure Prevalence, Incidence, and Mortality in the Elderly With Diabetes

1 reference

12 December 2020

Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide analogues for type 2 diabetes mellitus

1 reference

12 December 2020

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

1 reference

12 December 2020

10.1007/S40266-014-0155-7

Identifiers

DOI

1 reference

4 December 2017

1 reference